2023-508058-24-01RecruitingPhase 1
A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCER
Source: EU CTIS (euclinicaltrials.eu) · Last updated 21 Sept 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 1 Feb 2024
- Start date
- 5 Apr 2024
- Lead sponsor
- NovImmune S.A.
- Diseases
- Colorectal cancer
- EU CT number
- 2023-508058-24-01
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 12
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vall D'hebron Institut De Recerca | Barcelona | Spain | Recruiting |
| Hospital Universitario HM Sanchinarro | Madrid | Spain | Recruiting |
| Hospital Universitario Fundación Jiménez Díaz | Madrid | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.